Takeda Pharmaceutical (TAK) Long-Term Investments (2017 - 2026)

Takeda Pharmaceutical's Long-Term Investments history runs 10 years deep, the most recent figure standing at $56.1 million for Q1 2026.

• On a quarterly basis, Long-Term Investments fell 97.56% year-over-year to $56.1 million in Q1 2026; TTM through Mar 2026 was $56.1 million, a 97.56% decrease from a year earlier, with the FY2026 full-year figure at $58.4 million, down 97.47% from the prior year.
• Long-Term Investments fell to $56.1 million in Q1 2026 per TAK's latest filing, from $66.2 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $2.3 billion in Q1 2025 and bottomed at $56.1 million in Q1 2026.
• The 5-year median for Long-Term Investments is $698.9 million (2023), against an average of $753.9 million.
• Across the five-year window, Long-Term Investments jumped 154.42% in 2023 and sank 97.56% in 2026, its largest moves.
• Year by year, Long-Term Investments stood at $668.4 million in 2022, then increased by 4.57% to $698.9 million in 2023, then sank by 88.06% to $83.5 million in 2024, then retreated by 20.69% to $66.2 million in 2025, then retreated by 15.28% to $56.1 million in 2026.
• Per Business Quant, the three latest TAK Long-Term Investments figures stand at $56.1 million (Q1 2026), $66.2 million (Q4 2025), and $60.5 million (Q3 2025).